BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical today announced that its Aortic Intervention strategic business unit has captured more than 40 percent of the world market share, a leading global position in the endovascular aortic repair (EVAR) market. Through the rapid adoption of its advanced Zenith Endovascular Graft System designed to treat abdominal aortic aneurysms (AAA), the company has gained momentum as physicians, hospitals and other medical institutions have increasingly chosen Zenith as an effective, minimally invasive means of treating potentially life-threatening AAAs.
